The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence

Adil Eddie Bharucha, B. M. Seide, A. R. Zinsmeister

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background Women with faecal incontinence and rectal urgency have increased rectal stiffness and sensation. Aim To evaluate the effects of clonidine, an α2-adrenergic agonist, in faecal incontinence. Methods In this open-label uncontrolled study, bowel symptoms and anorectal functions (anal pressures, rectal compliance, and sensation) were assessed before and during treatment with transdermal clonidine (0.2 mg daily, 4 weeks) in 12 women with urge-predominant faecal incontinence. Results Clonidine reduced the frequency (17.8 ± 3.1 before vs. 8.8 ± 3.9 after, P = 0.03) and number of days with faecal incontinence (11.8 ± 1.6 before vs. 6.1 ± 1.8 after, P = 0.02), faecal incontinence symptom severity score (max = 13, 8.3 ± 0.7 vs. 5.6 ± 0.9, P < 0.01), and allowed patients to defer defecation for a longer duration (P = 0.03). Although overall effects on anorectal functions were not significant, the treatment-associated reduction in faecal incontinence episodes was associated with increased rectal compliance (r = -0.58, P < 0.05) and reduced rectal sensation. (r = -0.73, P = 0.007 vs. desire to defecate pressure threshold). Conclusions Clonidine improves symptoms in women with faecal incontinence; this improvement is associated with increased rectal compliance and reduced rectal sensitivity. A controlled study is necessary to confirm these observations.

Original languageEnglish (US)
Pages (from-to)681-688
Number of pages8
JournalAlimentary Pharmacology and Therapeutics
Volume32
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Fecal Incontinence
Clonidine
Compliance
Pressure
Adrenergic Agonists
Defecation
Hypesthesia
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence. / Bharucha, Adil Eddie; Seide, B. M.; Zinsmeister, A. R.

In: Alimentary Pharmacology and Therapeutics, Vol. 32, No. 5, 09.2010, p. 681-688.

Research output: Contribution to journalArticle

@article{c4755c49108b454fa37206accb7c4800,
title = "The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence",
abstract = "Background Women with faecal incontinence and rectal urgency have increased rectal stiffness and sensation. Aim To evaluate the effects of clonidine, an α2-adrenergic agonist, in faecal incontinence. Methods In this open-label uncontrolled study, bowel symptoms and anorectal functions (anal pressures, rectal compliance, and sensation) were assessed before and during treatment with transdermal clonidine (0.2 mg daily, 4 weeks) in 12 women with urge-predominant faecal incontinence. Results Clonidine reduced the frequency (17.8 ± 3.1 before vs. 8.8 ± 3.9 after, P = 0.03) and number of days with faecal incontinence (11.8 ± 1.6 before vs. 6.1 ± 1.8 after, P = 0.02), faecal incontinence symptom severity score (max = 13, 8.3 ± 0.7 vs. 5.6 ± 0.9, P < 0.01), and allowed patients to defer defecation for a longer duration (P = 0.03). Although overall effects on anorectal functions were not significant, the treatment-associated reduction in faecal incontinence episodes was associated with increased rectal compliance (r = -0.58, P < 0.05) and reduced rectal sensation. (r = -0.73, P = 0.007 vs. desire to defecate pressure threshold). Conclusions Clonidine improves symptoms in women with faecal incontinence; this improvement is associated with increased rectal compliance and reduced rectal sensitivity. A controlled study is necessary to confirm these observations.",
author = "Bharucha, {Adil Eddie} and Seide, {B. M.} and Zinsmeister, {A. R.}",
year = "2010",
month = "9",
doi = "10.1111/j.1365-2036.2010.04391.x",
language = "English (US)",
volume = "32",
pages = "681--688",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The effects of clonidine on symptoms and anorectal sensorimotor function in women with faecal incontinence

AU - Bharucha, Adil Eddie

AU - Seide, B. M.

AU - Zinsmeister, A. R.

PY - 2010/9

Y1 - 2010/9

N2 - Background Women with faecal incontinence and rectal urgency have increased rectal stiffness and sensation. Aim To evaluate the effects of clonidine, an α2-adrenergic agonist, in faecal incontinence. Methods In this open-label uncontrolled study, bowel symptoms and anorectal functions (anal pressures, rectal compliance, and sensation) were assessed before and during treatment with transdermal clonidine (0.2 mg daily, 4 weeks) in 12 women with urge-predominant faecal incontinence. Results Clonidine reduced the frequency (17.8 ± 3.1 before vs. 8.8 ± 3.9 after, P = 0.03) and number of days with faecal incontinence (11.8 ± 1.6 before vs. 6.1 ± 1.8 after, P = 0.02), faecal incontinence symptom severity score (max = 13, 8.3 ± 0.7 vs. 5.6 ± 0.9, P < 0.01), and allowed patients to defer defecation for a longer duration (P = 0.03). Although overall effects on anorectal functions were not significant, the treatment-associated reduction in faecal incontinence episodes was associated with increased rectal compliance (r = -0.58, P < 0.05) and reduced rectal sensation. (r = -0.73, P = 0.007 vs. desire to defecate pressure threshold). Conclusions Clonidine improves symptoms in women with faecal incontinence; this improvement is associated with increased rectal compliance and reduced rectal sensitivity. A controlled study is necessary to confirm these observations.

AB - Background Women with faecal incontinence and rectal urgency have increased rectal stiffness and sensation. Aim To evaluate the effects of clonidine, an α2-adrenergic agonist, in faecal incontinence. Methods In this open-label uncontrolled study, bowel symptoms and anorectal functions (anal pressures, rectal compliance, and sensation) were assessed before and during treatment with transdermal clonidine (0.2 mg daily, 4 weeks) in 12 women with urge-predominant faecal incontinence. Results Clonidine reduced the frequency (17.8 ± 3.1 before vs. 8.8 ± 3.9 after, P = 0.03) and number of days with faecal incontinence (11.8 ± 1.6 before vs. 6.1 ± 1.8 after, P = 0.02), faecal incontinence symptom severity score (max = 13, 8.3 ± 0.7 vs. 5.6 ± 0.9, P < 0.01), and allowed patients to defer defecation for a longer duration (P = 0.03). Although overall effects on anorectal functions were not significant, the treatment-associated reduction in faecal incontinence episodes was associated with increased rectal compliance (r = -0.58, P < 0.05) and reduced rectal sensation. (r = -0.73, P = 0.007 vs. desire to defecate pressure threshold). Conclusions Clonidine improves symptoms in women with faecal incontinence; this improvement is associated with increased rectal compliance and reduced rectal sensitivity. A controlled study is necessary to confirm these observations.

UR - http://www.scopus.com/inward/record.url?scp=77955162434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955162434&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2010.04391.x

DO - 10.1111/j.1365-2036.2010.04391.x

M3 - Article

VL - 32

SP - 681

EP - 688

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 5

ER -